Partner Investment Management L.P. decreased its holdings in Esperion Therapeutics Inc (NASDAQ:ESPR) by 21.1% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 25,440 shares of the biopharmaceutical company’s stock after selling 6,808 shares during the quarter. Partner Investment Management L.P. owned 0.09% of Esperion Therapeutics worth $1,129,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Opera Trading Capital acquired a new position in Esperion Therapeutics during the 3rd quarter worth approximately $173,000. Creative Planning increased its position in Esperion Therapeutics by 42.0% during the 3rd quarter. Creative Planning now owns 7,562 shares of the biopharmaceutical company’s stock worth $336,000 after purchasing an additional 2,236 shares in the last quarter. Keybank National Association OH increased its position in Esperion Therapeutics by 97.7% during the 2nd quarter. Keybank National Association OH now owns 7,663 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 3,787 shares in the last quarter. Metropolitan Life Insurance Co. NY increased its position in Esperion Therapeutics by 40.6% during the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 7,698 shares of the biopharmaceutical company’s stock worth $302,000 after purchasing an additional 2,224 shares in the last quarter. Finally, Canada Pension Plan Investment Board acquired a new position in Esperion Therapeutics during the 2nd quarter worth approximately $333,000.

A number of equities analysts recently issued reports on ESPR shares. Zacks Investment Research cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 6th. ValuEngine upgraded shares of Esperion Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Thursday, November 1st. BidaskClub cut shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, November 13th. BTIG Research assumed coverage on shares of Esperion Therapeutics in a research report on Tuesday, October 16th. They set a “buy” rating and a $82.00 price objective for the company. Finally, Northland Securities raised shares of Esperion Therapeutics from a “market perform” rating to an “outperform” rating and set a $65.00 target price on the stock in a report on Monday, October 29th. Two analysts have rated the stock with a sell rating, three have given a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $75.96.

In related news, Director Roger S. Newton sold 2,827 shares of the stock in a transaction on Friday, November 2nd. The shares were sold at an average price of $50.07, for a total transaction of $141,547.89. Following the transaction, the director now directly owns 573,953 shares of the company’s stock, valued at $28,737,826.71. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Roger S. Newton sold 9,400 shares of the stock in a transaction on Tuesday, October 16th. The stock was sold at an average price of $50.01, for a total transaction of $470,094.00. Following the transaction, the director now directly owns 589,326 shares in the company, valued at $29,472,193.26. The disclosure for this sale can be found here. Over the last three months, insiders have sold 152,327 shares of company stock worth $8,463,042. 14.50% of the stock is owned by insiders.

NASDAQ:ESPR opened at $53.51 on Wednesday. Esperion Therapeutics Inc has a 52 week low of $33.06 and a 52 week high of $82.68. The firm has a market capitalization of $1.43 billion, a PE ratio of -7.67 and a beta of 2.36.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, November 1st. The biopharmaceutical company reported ($1.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.64) by ($0.22). During the same quarter in the prior year, the company earned ($1.86) EPS. On average, sell-side analysts anticipate that Esperion Therapeutics Inc will post -6.59 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This story was first published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.watchlistnews.com/partner-investment-management-l-p-has-1-13-million-holdings-in-esperion-therapeutics-inc-espr/2662629.html.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Read More: How does inflation affect different investments?

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.